Stereotactic Radiosurgery for Brain Cancer

This trial examines a new approach to treating brain tumors in individuals with certain cancers, such as breast, lung, or melanoma. Researchers aim to determine if using stereotactic radiosurgery—a precise form of radiation therapy—before surgically removing a tumor can prevent cancer from spreading during the operation and improve recovery. Suitable candidates have a brain tumor that has not received this specific radiation treatment and is scheduled for surgical removal. As an unphased trial, this study provides patients the chance to contribute to groundbreaking research that could enhance future treatment options.

Research has shown that stereotactic radiosurgery (SRS) is generally a safe treatment with low rates of serious side effects. Studies have found that only about 5% of patients experienced major problems after receiving SRS. Since this treatment doesn't require cuts or incisions, it poses fewer risks than traditional surgery. Most people report mild side effects.

One study found that only a small number of patients developed issues like tissue damage or problems with the brain lining within two years, indicating that serious complications are uncommon.

Stereotactic radiosurgery (SRS) is unique because it delivers highly precise radiation beams to target brain tumors, minimizing damage to surrounding healthy tissue. Unlike traditional whole-brain radiation therapy, which can affect large areas of the brain, SRS focuses only on the tumor, potentially reducing side effects and improving recovery times. Researchers are excited about SRS because it can be combined with surgical resection to potentially enhance treatment effectiveness, offering a more targeted and less invasive option for brain cancer patients.

Research has shown that stereotactic radiosurgery (SRS), a treatment under study in this trial, effectively treats brain tumors. Studies have found that SRS stops tumor growth in about 90% of cases within six months. It is safer than traditional surgery because it involves no cutting. Patients often experience mild side effects, such as tiredness, which usually peak within a couple of weeks. Importantly, SRS has been linked to better tumor control in the treated area compared to whole-brain radiation therapy. This suggests that SRS can be a strong option for effectively managing brain tumors.¹²⁴⁶⁷